---All---
  • ---All---
  • Accession
  • Catalog #

AGO1 Antibody (N-term)Purified Rabbit Polyclonal Antibody (Pab)

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
AP6558a 0.1 mg 400 ul In Stock $ 255.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

AGO1 Antibody (N-term) - Product info

ApplicationWB, IHC
  • Applications Legend:
  • W=Western Blotting
  • IP=Immunoprecipitation
  • IHC-P=Immunohistochemistry (Paraffin)
  • IF-IC=Immunofluorescence (Immunocytochemistry)
  • F=Flow Cytometry
Primary AccessionQ9UL18
Other AccessionQ8CJG1
ReactivityHuman
PredictedMouse
Concentration0.25 mg/ml
IsotypeRabbit Ig
Calculated MW97214 Da

AGO1 Antibody (N-term) - Additional info

Gene ID 26523
Other Names
EIF2C1; AGO1; Protein argonaute-1; Eukaryotic translation initiation factor 2C 1; Putative RNA-binding protein Q99
Target/Specificity
This AGO1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 34~64 amino acids from the N-terminal region of human AGO1.
Dilution
WB~~1:50~100
IHC~~1:50~100
Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions
AGO1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

AGO1 Antibody (N-term) - Protein Information

Name EIF2C1
Synonyms AGO1
Function
Required for RNA-mediated gene silencing (RNAi). Binds to short RNAs such as microRNAs (miRNAs) or short interfering RNAs (siRNAs), and represses the translation of mRNAs which are complementary to them. Lacks endonuclease activity and does not appear to cleave target mRNAs. Also required for transcriptional gene silencing (TGS) of promoter regions which are complementary to bound short antigene RNAs (agRNAs)
Cellular Location
Cytoplasm, P-body.

AGO1 Antibody (N-term) - Related products

AP6558a: AGO1 Antibody (N-term)

RI11717: EIF2C1 predesign siRNA

BP6558a: AGO1 Antibody (N-term) Blocking Peptide

AF1359a: EIF2C1 Antibody

AGO1 Antibody (N-term) - Application data

  • Western blot analysis of AGO1 Antibody (N-term) (Cat. #AP6558a) in K562 cell line lysates (35ug/lane). AGO1 (arrow) was detected using the purified Pab.

  • AGO1 Antibody (N-term) (RB18965) IHC analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the AGO1 Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.

AGO1 Antibody (N-term) - Research Areas

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

AGO1 is a member of the Argonaute family of proteins which play a role in RNA interference. The protein is highly basic, and contains a PAZ domain and a PIWI domain. It may interact with dicer1 and play a role in short-interfering-RNA-mediated gene silencing.

REFERENCES

Weinmann,L., Cell 136 (3), 496-507 (2009) Horikawa,Y., Clin. Cancer Res. 14 (23), 7956-7962 (2008)